Molecular Biosystems reported a drop in profits on a slight increase in revenue for the second quarter ended Sept. 30.
The manufacturer of human diagnostic products posted a profit of $155,431 on sales of $1.6 million for the quarter, down from a profit of $445,767 on revenue of $1.3 million in the comparable year-before period. For the first six months this fiscal year, Molecular Biosystems’ profit stands at $386,673 on sales of $3.1 million, down from a profit of $406,465 on revenue of $2.2 million the previous year.
Of Molecular Biosystems’ second-quarter revenue, $55,000 came from the sale of products, contrasted with $46,000 over the year-before period. The rest came from research and license fees, including $730,000 from Nycomed, a Norwegian pharmaceutical firm that last year acquired rights to test and market Albunex, an ultrasound contrast agent Molecular Biosystems is developing.